Literature DB >> 18613405

Clinical significance of serum HGF and c-Met expression in tumor tissue for evaluation of properties and treatment of hepatocellular carcinoma.

Shinji Osada1, Masayuki Kanematsu, Hisashi Imai, Satoshi Goshima.   

Abstract

BACKGROUND/AIMS: To develop a prognostic marker for evaluation of intrahepatic metastasis (IM) of hepatocellular carcinoma (HCC), the ligand-stimulated receptor activity of c-Met due to hepatocyte growth factor (HGF) was estimated.
METHODOLOGY: For specimens from 30 HCC patients, who were operated on at the Department of Surgical Oncology, Gifu University School of Medicine, for 2 recent years, the induction value of HGF and c-Met were estimated by western blot.
RESULTS: Firstly, the serum HGF levels were significantly higher in invasive gross type or in IM-positive tumors. Secondly, the mean expression value of HGF protein in tumors was 0.56 +/- 0.35, which was not different from non-tumor tissue, 0.59 +/- 0.40. And there was no significant differences based on tumor profiles. Thirdly, the value of c-Met in tumor tissue, 1.36 +/- 0.12, was clearly higher than in non-tumor tissue, 1.07 +/- 0.06. The c-Met expressions were significantly higher in the invasive type of HCC as determined by gross type, vessel invasion, IM presence and histological type. Finally, in individual studies about the relationship between the level of serum HGF and c-Met expression in tumor tissue, the presence of IM could be easily detected. Furthermore, the level of serum HGF after hepatectomy was significantly higher than the preoperative value, and individual studies with c-Met expression were associated with early recurrence.
CONCLUSIONS: The induction of c-Met might be important to evaluate the progression of HCC, especially to caution for the presence of IM.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18613405

Source DB:  PubMed          Journal:  Hepatogastroenterology        ISSN: 0172-6390


  29 in total

Review 1.  Management of hepatocellular carcinoma: beyond sorafenib.

Authors:  Stephen L Chan; Tony Mok; Brigette B Y Ma
Journal:  Curr Oncol Rep       Date:  2012-06       Impact factor: 5.075

Review 2.  MET inhibitors for treatment of advanced hepatocellular carcinoma: A review.

Authors:  Xing-Shun Qi; Xiao-Zhong Guo; Guo-Hong Han; Hong-Yu Li; Jiang Chen
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

Review 3.  Development of systemic therapy for hepatocellular carcinoma at 2013: updates and insights.

Authors:  Stephen L Chan; Winnie Yeo
Journal:  World J Gastroenterol       Date:  2014-03-28       Impact factor: 5.742

4.  Epithelial-to-mesenchymal transition of murine liver tumor cells promotes invasion.

Authors:  Wei Ding; Hanning You; Hien Dang; Francis LeBlanc; Vivian Galicia; Shelly C Lu; Bangyan Stiles; C Bart Rountree
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

5.  Silencing CircEIF3I/miR-526b-5p Axis Epigenetically Targets HGF/c-Met Signal to Hinder the Malignant Growth, Metastasis and Angiogenesis of Hepatocellular Carcinoma.

Authors:  Yang Liu; Xia Xiao; Jingying Wang; Yitong Wang; Yanhui Yu
Journal:  Biochem Genet       Date:  2022-06-20       Impact factor: 1.890

6.  Low temperature of radiofrequency ablation at the target sites can facilitate rapid progression of residual hepatic VX2 carcinoma.

Authors:  Shan Ke; Xue-mei Ding; Jian Kong; Jun Gao; Shao-hong Wang; Yan Cheng; Wen-bing Sun
Journal:  J Transl Med       Date:  2010-07-29       Impact factor: 5.531

Review 7.  Molecular targeted therapy in hepatocellular carcinoma: from biology to clinical practice and future.

Authors:  Anuj Patel; Weijing Sun
Journal:  Curr Treat Options Oncol       Date:  2014-09

8.  Tumor-derived hepatocyte growth factor is associated with poor prognosis of patients with glioma and influences the chemosensitivity of glioma cell line to cisplatin in vitro.

Authors:  You-Feng Guo; Xiao-Bing Wang; Xiao-Ying Tian; Yang Li; Bin Li; Quan Huang; Meng Zhang; Zhi Li
Journal:  World J Surg Oncol       Date:  2012-06-28       Impact factor: 2.754

9.  Targeted therapies in the treatment of advanced hepatocellular carcinoma.

Authors:  Zhengyu Wei; Cataldo Doria; Yuan Liu
Journal:  Clin Med Insights Oncol       Date:  2013-05-20

10.  Targeting the HGF-cMET Axis in Hepatocellular Carcinoma.

Authors:  Neeta K Venepalli; Laura Goff
Journal:  Int J Hepatol       Date:  2013-03-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.